Enzo Q1 Revenues up 6 Percent, Reaches CDx Deal with Flagship Bio | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market yesterday a 6 percent drop in its FY 2014 revenues year over year.

Separately, the firm announced today a deal with Flagship Biosciences to develop companion diagnostics for anatomic pathology applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.